Prostate Cell News 1.30, August 13, 2010.
In this issue: Science News | Current Publications | Industry News | Policy News | Events Subscribe | Unsubscribe
Local Prolactin Is a Target to Prevent Expansion of Basal/Stem Cells in Prostate Tumors
Study identified prolactin (PRL) receptor/Stat5 as a unique pathway, initiating prostate tumorogenesis by altering basal-/stem-like cell subpopulations, and strongly supports the importance of further developing strategies to target locally overexpressed PRL in human prostate cancer. [Proc Natl Sci USA]
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult™
by STEMCELL Technologies
Surgery Better Than Radiation, Hormones for Some Prostate Cancer
Surgery for localized prostate cancer offers a significantly higher survival rate than either external-beam radiation or hormonal therapies. [Press release from the University of California, San Francisco discussing online prepublication in Cancer]
Rutgers Researchers Assess Severity of Prostate Cancers Using Non-Invasive Magnetic Resonance Imaging
Rutgers researchers are developing methods that can accurately assess the severity of prostate cancer by analyzing magnetic resonance images and spectra of a patient's prostate gland. [Rutgers Press Release]
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)
Reciprocal Activation of Prostate Cancer Cells and Cancer-Associated Fibroblasts Stimulates Epithelial-Mesenchymal Transition and Cancer Stemness
Analysis of the mutual interplay between prostate carcinoma cells and cancer-associated fibroblasts revealed a mandatory role of carcinoma-derived interleukin-6 in fibroblast activation. In turn, activated fibroblasts through secretion of metalloproteinases elicit in cancer cells a clear epithelial-mesenchymal transition, as well as enhancement of tumor growth and development of spontaneous metastases. [Cancer Res]
Mineralized Human Primary Osteoblast Matrices as a Model System to Analyse Interactions of Prostate Cancer Cells with the Bone Microenvironment
Investigators hypothesized that matrices produced by primary human osteoblasts are a suitable means to develop an in vitro model system for bone metastasis research mimicking in vivo conditions. [Biomaterials]
Global Reactivation of Epigenetically Silenced Genes in Prostate Cancer
Two important findings were, first, that several genes known to be frequently hypermethylated in prostate cancer were apparent, and, second, that validation studies revealed eight novel genes hypermethylated in the prostate tumor cell lines, four of which were unmethylated in normal prostate cells and hypermethylated in primary prostate tumors. [Cancer Prev Res]
p53-Dependent Induction of Prostate Cancer Cell Senescence by the PIM1 Protein Kinase
In human 22Rv1 cells, the induction of p53 protein was associated not only with senescence but also with a significant level of apoptosis. [Mol Cancer]
Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in Relation to Prostate Cancer Risk
In a population-based case-control study designed to investigate the relation between these medications and prostate cancer risk, detailed exposure data were analyzed from 1,001 cases diagnosed with prostate cancer between January 1, 2002, and December 31, 2005, and 942 age-matched controls from King County, Washington. [Am J Epidemiol]
Comparative Risk-Adjusted Mortality Outcomes after Primary Surgery, Radiotherapy, or Androgen-Deprivation Therapy for Localized Prostate Cancer
Because no adequate randomized trials have compared active treatment modalities for localized prostate cancer, the authors analyzed risk-adjusted, cancer-specific mortality outcomes among men who underwent radical prostatectomy, men who received external-beam radiation therapy, and men who received primary androgen-deprivation therapy. [Cancer]
Knowledge and Use of Finasteride for the Prevention of Prostate Cancer
Researchers examined the influence of the Prostate Cancer Prevention Trial on finasteride prescribing within the Veterans Health Administration. [Cancer Epidemiol Biomarkers Prev]
Efficacy of S-1 in Patients with Castration-Resistant Prostate Cancer: A Phase II Study
This study was conducted to evaluate the efficacy and safety of S-1, an oral fluoropyrimidine derivative, in Japanese patients with castration-resistant prostate cancer. [Oncology]
Genetic Variation in Adiponectin and the Type 1 Receptor (ADIPOR1), Obesity and Prostate Cancer in African Americans
Investigators examined the relationship between polymorphisms in the adiponectin gene (ADIPOQ) and its type 1 receptor (ADIPOR1) genes, obesity and prostate cancer in study of African-American men. [Prostate Cancer Prostatic Dis]
Miraculins Launches ELISA Kit for PSP94 and Announces Distribution Agreement with GenWay Biotech
Miraculins Inc. announced the launch of its PSP94 Immunoassay for urine specimens, a research use only tool utilizing enzyme linked immunosorbent assay for the detection of PSP94 in urine. [Miraculins, Inc. Press Release]
Augmenix Announces First Commercial Use of SpaceOAR™ System for Prostate-Rectum Separation in Prostate Cancer Patients Undergoing Radiation Therapy
Augmenix, Inc. announced that Prof. Michael Eble and Dr. Michael Pinkawa of the Aachen University Hospital performed a commercial implantation of the company's CE Mark approved SpaceOAR™ System. [Augmenix Press Release]
Aragon Pharmaceuticals Doses First Patient in Phase I/II Clinical Trial of ARN-509 for Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals announced the dosing of the first patient in a Phase I/II clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer. [Aragon Pharmaceuticals Press Release]
GenSpera Receives Additional Patent on Lead Oncology Prodrug, G-202
GenSpera, Inc. announced that its patent application, entitled "Tissue Specific Prodrugs," has been issued by the United States Patent and Trademark Office as U.S. Patent 7,767,648. [GenSpera Press Release]
Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
Aeterna Zentaris Inc. announced that the National Institutes of Health has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US$1.5 million over three years to conduct a Phase I/II study in refractory prostate cancer with the Company's doxorubicin luteinizing hormone-releasing hormone receptor targeted conjugate compound, AEZS-108. [Aeterna Zentaris Inc. Press Release]
Kansas State Professor's Cancer Research gets Boost from National Institutes of Health
Annelise Nguyen recently received a $370,000 grant from the National Institutes of Health to continue her cancer research. [Kansas State University Press Release]
Dendreon Reports Second Quarter 2010 Financial Results
Dendreon Corporation reported results for the quarter ended June 30, 2010. [Dendreon Corporation Press Release]
Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
Soligenix, Inc. announced its financial results for the second quarter of 2010. [Soligenix, Inc]
Fred Hutchinson Cancer Research Center Announces Selection of Its New President and Director
The Fred Hutchinson Cancer Research Center board of trustees announced the selection of Lawrence Corey as its new president and director. [Fred Hutchinson Cancer Research Center Press Release]
Craig Thompson Named President of Memorial Sloan-Kettering Cancer Center
Craig B. Thompson has been named the new President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center effective November 2, 2010. [Memorial Sloan-Kettering Cancer Center Press Release]
Roswell Park Cancer Institute Explores Research Collaboration with Wilmot Cancer Center
Roswell Park Cancer Institute and The University of Rochester Medical Center's James P. Wilmot Cancer Center announced that they are exploring a regional scientific alliance. [Roswell Park Cancer Institute Press Release]
Information Sent to Healthcare Professionals in July 2010 About the Safety of Medicines
A list of letters sent to healthcare professionals in July 2010, to inform of new safety information and advice about medicines. [Medicines and Healthcare Products Regulatory Agency, United Kingdom]
Adverse Drug Reactions: Update on Anonymized Single Patient Reports (ASPRs): July 2010
The MHRA has implemented a series of changes to the logic which defines which marketing authorization holders receive ASPRs/Individual Case Safety Reports. [Medicines and Healthcare Products Regulatory Agency, United Kingdom]
Scientists Decry Proposed Ban on Chimp Research
In the latest twist in the protracted debate over the use of chimpanzees in biomedical research, U.S. senators introduced the Great Ape Protection Act, an identical bill to one that has been stuck in a House of Representatives committee for more than a year. [Senate, United States]
Chimpanzee Biomedical Research Program Limited Competition (U42) (RFA-RR-10-008) [National Institutes of Health, United States]
Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-19167) [National Institutes of Health, United States]
National Human Genome Research Institute; Notice of Meeting (FR Doc. 2010-19165)[National Institutes of Health, United States]
Solicitation for Nominations: New Clinical Preventive Health for the United States Preventive Services Task Force, [2010-19117][Agency for Healthcare Research and Quality, United States]
2010 Biological License Application Approvals [Center for Biologics Evaluation and Research, United States]
2010 Biological License Application Supplement Noteworthy Approvals[Center for Biologics Evaluation and Research, United States]
2010 Biological Device Application Approvals [Center for Biologics Evaluation and Research, United States]
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Procedures for the Clinical Laboratory Improvement Amendments of 1988 Categorization [Docket No. FDA-2010-N-0199][Food and Drug Administration, United States]
Clinical Studies of Safety and Effectiveness of Orphan Products Research Project Grant (R01) [Docket No. FDA-2010-N-0394] [Food and Drug Administration, United States]
Guidance for Industry on Drug Substance Chemistry, Manufacturing, and Controls Information; Availability [Docket No. FDA-2003-D-0243] [Food and Drug Administration, United States]
EVENTS (Listed by Date)
CHI's 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS)
2010 World Cancer Congress
Ninth International Congress on Targeted Therapies in Cancer
Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
Select Biosciences Inaugural Cellular Therapy Summit
Select Biosciences 2nd Annual World Biobanking Summit
Select Biosciences 3rd Annual Stem Cells Europe Conference
The Science of Global Prostate Cancer Disparities in Black Men
28th World Congress of Endourology and SWL
Prostate Cancer Research Institute Conference 2010
International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
Belgirate, Italy
Tissue Engineering and Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
2010 Prostate Cancer Canada (PCCN) Conference
NEW International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations
35th European Society for Medical Oncology (ESMO) Congress
October 8–12, 2010
Frontiers in Tumour Progression
Cancer Pharmacogenetics: Personalising Medicine
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
Cell Therapy Technologist (Opexa Therapeutics)
Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Prostate Cell News.
Visit here to post your career opportunities.
Learn more about Prostate Cell News: Archives | Events | Subscribe | Contact Us